

In the claims:

1. (Currently Amended) A method of treatment of an individual suffering from a disease resulting from an abnormal expression of genes caused by aberrant splicing in cells due to either exon inclusion, exon skipping or both exon inclusion and exon skipping the method being cystic fibrosis comprising:

administering to, or expressing in, said cells of the individual or to cells, tissue or organs of said individual in need thereof comprising said cells, an effective amount of an alternative splicing factor (ASF) capable of at least partially correcting aberrant splicing of a transcript of a CTRF gene, thereby treating cystic fibrosis in said individual for treating exon inclusion, exon skipping or both exon inclusion and exon skipping whereby said abnormal expression shifts towards normal expression of the gene.

2. (Cancelled)

3. (Currently Amended) A method according to Claim 21, wherein the aberrant splicing is caused by a mutation 3849+10kb C>T of the said CTRF gene.

4. (Currently Amended) A method according to Claim 21, wherein the aberrant splicing is caused by a mutation in the 5T allele of the said CTRF gene.

5. (Currently Amended) A method according to Claim 1, wherein the said ASF is selected from the group consisting of:

- (a) a member of the SR protein;
- (b) heterogeneous nuclear ribonucleoprotein A1;
- (c) viral factor E4-ORF3; and
- (d) viral factor E4-ORF6; and
- (e) an agonist of any one of (a) to (e).

6. (Currently Amended) A method according to Claim 1, wherein the said ASF is administered ~~to the cells or to the tissue or organs comprising the cells~~ in a pharmaceutically acceptable vehicle.

7. (cancelled)

8. (Currently Amended) A method according to Claim 6, wherein the said ASF is attached to a targeting moiety capable of binding specifically to said cells.